FAQ: Calidi Biotherapeutics' Presentation at H.C. Wainwright Global Investment Conference

What is the main topic of this announcement?

Calidi Biotherapeutics CEO Eric Poma, Ph.D. will present at the H.C. Wainwright 27th Annual Global Investment Conference, focusing on the company’s RedTail platform for delivering genetic medicines to metastatic cancer sites.

When and where is the conference taking place?

The conference is scheduled for September 8-10, 2025, at the Lotte New York Palace Hotel in New York City.

What is Calidi Biotherapeutics’ RedTail platform?

The RedTail platform is an engineered enveloped oncolytic virus designed for systemic delivery that protects the virus from immune clearance, induces tumor lysis, and delivers therapeutic genetic medicines to metastatic sites.

When will the on-demand presentation be available?

The on-demand presentation will be available starting September 5, 2025, at 7 a.m. Eastern Time.

What types of cancer is Calidi’s lead candidate targeting?

The lead candidate from the Redtail platform is targeting non-small cell lung cancer, ovarian cancer, and other tumor types with high unmet medical need, currently in IND-enabling studies.

Where can I find more information about Calidi Biotherapeutics?

The latest news and updates relating to CLDI are available in the company’s newsroom at https://ibn.fm/CLDI, and the full press release can be viewed at https://ibn.fm/85iH4.

What is TinyGems and its role in this announcement?

TinyGems is a specialized communications platform focused on innovative small-cap and mid-cap companies, providing access to wire solutions, editorial syndication, press release enhancement, and social media distribution through the Investor Brand Network.

What are the potential benefits of Calidi’s technology?

The technology is designed to shield viruses from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent gene therapies to metastatic locations through systemic administration.